283 related articles for article (PubMed ID: 22364141)
1. A switch in therapy to a reverse transcriptase inhibitor sparing combination of lopinavir/ritonavir and raltegravir in virologically suppressed HIV-infected patients: a pilot randomized trial to assess efficacy and safety profile: the KITE study.
Ofotokun I; Sheth AN; Sanford SE; Easley KA; Shenvi N; White K; Eaton ME; Del Rio C; Lennox JL
AIDS Res Hum Retroviruses; 2012 Oct; 28(10):1196-206. PubMed ID: 22364141
[TBL] [Abstract][Full Text] [Related]
2. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
Reynes J; Lawal A; Pulido F; Soto-Malave R; Gathe J; Tian M; Fredrick LM; Podsadecki TJ; Nilius AM
HIV Clin Trials; 2011; 12(5):255-67. PubMed ID: 22180523
[TBL] [Abstract][Full Text] [Related]
3. HIV lipodystrophy in participants randomised to lopinavir/ritonavir (LPV/r) +2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI) or LPV/r + raltegravir as second-line antiretroviral therapy.
Martin A; Moore CL; Mallon PW; Hoy JF; Emery S; Belloso WH; Phanuphak P; Ferret S; Cooper DA; Boyd MA;
PLoS One; 2013; 8(10):e77138. PubMed ID: 24204757
[TBL] [Abstract][Full Text] [Related]
4. Raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: a randomised open label study for the treatment of HIV-1 infection.
Amin J; Boyd MA; Kumarasamy N; Moore CL; Losso MH; Nwizu CA; Mohapi L; Kerr SJ; Sohn AH; Teppler H; Renjifo B; Molina JM; Emery S; Cooper DA
PLoS One; 2015; 10(2):e0118228. PubMed ID: 25723472
[TBL] [Abstract][Full Text] [Related]
5. 48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis.
Patel DA; Snedecor SJ; Tang WY; Sudharshan L; Lim JW; Cuffe R; Pulgar S; Gilchrist KA; Camejo RR; Stephens J; Nichols G
PLoS One; 2014; 9(9):e105653. PubMed ID: 25188312
[TBL] [Abstract][Full Text] [Related]
6. Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial.
Orkin C; DeJesus E; Khanlou H; Stoehr A; Supparatpinyo K; Lathouwers E; Lefebvre E; Opsomer M; Van de Casteele T; Tomaka F
HIV Med; 2013 Jan; 14(1):49-59. PubMed ID: 23088336
[TBL] [Abstract][Full Text] [Related]
7. A nucleoside- and ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naïve HIV-infected patients: SPARTAN study results.
Kozal MJ; Lupo S; DeJesus E; Molina JM; McDonald C; Raffi F; Benetucci J; Mancini M; Yang R; Wirtz V; Percival L; Zhang J; Zhu L; Arikan D; Farajallah A; Nguyen BY; Leavitt R; McGrath D; Lataillade M; The Spartan Study Team
HIV Clin Trials; 2012; 13(3):119-30. PubMed ID: 22592092
[TBL] [Abstract][Full Text] [Related]
8. Improvement of lipoatrophy by switching from efavirenz to lopinavir/ritonavir.
Rojas J; Lonca M; Imaz A; Estrada V; Asensi V; Miralles C; Domingo P; Montero M; del Rio L; Fontdevila J; Perez I; Cruceta A; Gatell JM; Arnedo M; Martínez E
HIV Med; 2016 May; 17(5):340-9. PubMed ID: 27089862
[TBL] [Abstract][Full Text] [Related]
9. Pilot, randomized study assessing safety, tolerability and efficacy of simplified LPV/r maintenance therapy in HIV patients on the 1 PI-based regimen.
Cahn P; Montaner J; Junod P; Patterson P; Krolewiecki A; Andrade-Villanueva J; Cassetti I; Sierra-Madero J; Casiró AD; Bortolozzi R; Lupo SH; Longo N; Rampakakis E; Ackad N; Sampalis JS
PLoS One; 2011; 6(8):e23726. PubMed ID: 21886816
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of three antiretroviral therapy regimens for treatment-naive African adults living with HIV-2 (FIT-2): a pilot, phase 2, non-comparative, open-label, randomised controlled trial.
Eholie SP; Ekouevi DK; Chazallon C; Charpentier C; Messou E; Diallo Z; Zoungrana J; Minga A; Ngom Gueye NF; Hawerlander D; Dembele F; Colin G; Tchounga B; Karcher S; Le Carrou J; Tchabert-Guié A; Toni TD; Ouédraogo AS; Bado G; Toure Kane C; Seydi M; Poda A; Mensah E; Diallo I; Drabo YJ; Anglaret X; Brun-Vezinet F;
Lancet HIV; 2024 Jun; 11(6):e380-e388. PubMed ID: 38740027
[TBL] [Abstract][Full Text] [Related]
11. Lopinavir/ritonavir combined with raltegravir or tenofovir/emtricitabine in antiretroviral-naive subjects: 96-week results of the PROGRESS study.
Reynes J; Trinh R; Pulido F; Soto-Malave R; Gathe J; Qaqish R; Tian M; Fredrick L; Podsadecki T; Norton M; Nilius A
AIDS Res Hum Retroviruses; 2013 Feb; 29(2):256-65. PubMed ID: 22730929
[TBL] [Abstract][Full Text] [Related]
12. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.
Mills AM; Nelson M; Jayaweera D; Ruxrungtham K; Cassetti I; Girard PM; Workman C; Dierynck I; Sekar V; Abeele CV; Lavreys L
AIDS; 2009 Aug; 23(13):1679-88. PubMed ID: 19487905
[TBL] [Abstract][Full Text] [Related]
13. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.
Boyd MA; Amin J; Mallon PW; Kumarasamy N; Lombaard J; Wood R; Chetchotisakd P; Phanuphak P; Mohapi L; Azwa I; Belloso WH; Molina JM; Hoy J; Moore CL; Emery S; Cooper DA;
Lancet HIV; 2017 Jan; 4(1):e13-e20. PubMed ID: 27815068
[TBL] [Abstract][Full Text] [Related]
14. Meta-analysis of the safety, tolerability, and efficacy of lopinavir/ritonavir-containing antiretroviral therapy in HIV-1-infected women.
Hermes A; Squires K; Fredrick L; Martinez M; Pasley M; Trinh R; Norton M
HIV Clin Trials; 2012; 13(6):308-23. PubMed ID: 23195669
[TBL] [Abstract][Full Text] [Related]
15. A pilot study of switch to lopinavir/ritonavir (LPV/r) monotherapy from nonnucleoside reverse transcriptase inhibitor-based therapy.
Pierone G; Mieras J; Bulgin-Coleman D; Kantor C; Shearer J; Fontaine L; Fath M; Norton M
HIV Clin Trials; 2006; 7(5):237-45. PubMed ID: 17162317
[TBL] [Abstract][Full Text] [Related]
16. First-line antiretroviral therapy with nevirapine versus lopinavir-ritonavir based regimens in a resource-limited setting.
Clumeck N; Mwamba C; Kabeya K; Matanda S; Vaira D; Necsoi C; Kadiebwe D; Delforge M; Kasamba E; Milolo C; Ilunga J; Kapend L
AIDS; 2014 May; 28(8):1143-53. PubMed ID: 25028911
[TBL] [Abstract][Full Text] [Related]
17. Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings.
Bartlett JA; Ribaudo HJ; Wallis CL; Aga E; Katzenstein DA; Stevens WS; Norton MR; Klingman KL; Hosseinipour MC; Crump JA; Supparatpinyo K; Badal-Faesen S; Kallungal BA; Kumarasamy N
AIDS; 2012 Jul; 26(11):1345-54. PubMed ID: 22441252
[TBL] [Abstract][Full Text] [Related]
18. Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapy.
Martin A; Moore C; Mallon PW; Hoy J; Emery S; Belloso W; Phanuphak P; Ferret S; Cooper DA; Boyd MA;
AIDS; 2013 Sep; 27(15):2403-11. PubMed ID: 23921615
[TBL] [Abstract][Full Text] [Related]
19. Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial.
Cooper DA; Cordery DV; Zajdenverg R; Ruxrungtham K; Arastéh K; Bergmann F; Neto JL; Scherer J; Chaves RL; Robinson P;
PLoS One; 2016; 11(1):e0144917. PubMed ID: 26730818
[TBL] [Abstract][Full Text] [Related]
20. Monotherapy with Lopinavir/Ritonavir as maintenance after HIV-1 viral suppression: results of a 96-week randomized, controlled, open-label, pilot trial (KalMo study).
Nunes EP; Santini de Oliveira M; Merçon M; Zajdenverg R; Faulhaber JC; Pilotto JH; Ribeiro JE; Norton M; Schechter M
HIV Clin Trials; 2009; 10(6):368-74. PubMed ID: 20133267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
